Penn Institute for Urban Research

CHOP and Penn Medicine Researchers Develop "In Vivo" RNA-based Gene Editing Model for Blood Disorders

Retrieved on: 
Thursday, July 27, 2023
Nanoparticle, Bone marrow, Doctor of Philosophy, Bangladesh Technical Education Board, COVID-19 vaccine, MD, Patient, Division, Risk, Thomas, Perelman School of Medicine at the University of Pennsylvania, LNP Media Group, CD117, DSM-IV codes, Infection, Disease, Children's Hospital of Philadelphia, Tissue, Hematologic disease, BS, University, Pediatrics, Therapy, CHOP, Hematology, Gene editing, Biomedical Research, Mutation, Research, Penn Institute for Urban Research, DOI, Hospital, HSC, NIH, Vaccine, Hematopoietic stem cell, Stem cell, COVID-19, Philadelphia, Cell, Child, Antibody, Messenger, Blood, Immune system, LNP, Radiation, Doctor of Pharmacy, Cell death, PUMA, SCID, Sickle cell disease, RNA, Penn, Health, Dicarboxylic acid, Dentistry, Pharmaceutical industry, Science

PHILADELPHIA, July 27, 2023 /PRNewswire/ -- In a step forward in the development of genetic medicines, researchers at Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania have developed a proof-of-concept model for delivering gene editing tools to treat blood disorders, allowing for the modification of diseased blood cells directly within the body. If translated into the clinic, this approach could expand access and reduce the cost of gene therapies for blood disorders, many of which currently require patients receive chemotherapy and a stem cell transplant. The findings were published today in the journal Science.

Key Points: 
  • This approach could expand access and reduce the cost of gene therapies for blood disorders.
  • A targeted mRNA-encoded genomic editing methodology could lead to controlled expression, high editing efficacy, and potentially safer in vivo genomic modification compared to currently available technologies."
  • In patients with non-malignant hematopoietic disorders like sickle cell disease and immunodeficiency disorders, these blood cells don't function correctly because they carry a genetic mutation.
  • First, the researchers tested CD117/LNP encapsulating reporter mRNA to show successful in vivo mRNA expression and gene editing.

Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering

Retrieved on: 
Wednesday, September 14, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Other Health, RNA transfection, Research, Patient, Kite Pharma, Penn Institute for Urban Research, Perelman School of Medicine at the University of Pennsylvania, Technology, Cell, Drug development, Cell engineering, CAR, University, Fibrosis, FAP, Gorilla, Company, Investment, Kite, MBA, Translational medicine, Polaris Partners, LNP, SM-102, Laboratory, Lasker-DeBakey Clinical Medical Research Award, Pharming, CEO, Therapy, Engineering, LinkedIn, Immunotherapy, CA, RNA, Bristol Myers Squibb, Penn, Regenerative medicine, Pharmaceutical industry, Vaccine, Management, Capstan, Aghajanyan, DRS, Science

Capstan also plans to leverage its precision delivery and engineering technology to advance new therapies for certain monogenic blood disorders.

Key Points: 
  • Capstan also plans to leverage its precision delivery and engineering technology to advance new therapies for certain monogenic blood disorders.
  • Capstan is also pleased to announce that Laura Shawver, Ph.D., has joined the company as President and Chief Executive Officer.
  • Our ambition at Capstan is to invent new clinical paradigms through targeted in vivo reprogramming of cells, said Dr. Shawver.
  • Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.

Toorak Capital Partners Appoints Two Industry Veterans to Board of Directors

Retrieved on: 
Wednesday, December 1, 2021
Finance, Professional Services, Residential Building & Real Estate, Construction & Property, Human Resources, RMBS, KKR, Partnership, State, Industry, Morgan Stanley, Bedford–Stuyvesant, Brooklyn, Business school, UBS, MBA, Fordham University, Partnership for New York City, Virginia Foundation for the Humanities, University, Leadership, Risk management, Business, City, Global, Enterprise, CLO, Penn Institute for Urban Research, Bedford Stuyvesant Restoration Corporation, Credit Suisse, CrossHarbor Capital Partners, Urban planning, LLC, Deutsche Bank, Board of directors, BlackRock, Roger Clinton Sr., Government National Mortgage Association, University of Virginia School of Architecture, ABS, Multimedia, Virginia School for Girls, Enterprise Community Partners, Growth, Harvard Law School, Real estate, Management

Toorak Capital Partners, Inc. (Toorak), a leading capital provider to real estate lenders, today announced the appointment of Kevin Chavers and Francis Byrne to the companys Board of Directors.

Key Points: 
  • Toorak Capital Partners, Inc. (Toorak), a leading capital provider to real estate lenders, today announced the appointment of Kevin Chavers and Francis Byrne to the companys Board of Directors.
  • Kevin and Francis bring decades of industry experience, and I am certain Toorak will significantly benefit from their leadership and guidance.
  • With capital commitments from entities managed by KKR, a leading global investment firm, Toorak Capital Partners has revolutionized the way business purpose residential real estate lenders access capital.
  • To learn more about Toorak Capital Partners correspondent lending platform, please contact the firm at [email protected] or 212-393-4100.

Volcker Alliance and Penn Institute for Urban Research Launch Web Series on Fiscal Impact of COVID-19

Retrieved on: 
Monday, April 20, 2020
Penn Institute for Urban Research, Sustainable urban planning, University of Pennsylvania, Urbanization, Institute for Operations Research and the Management Sciences, Academic disciplines

NEW YORK, April 20, 2020 /PRNewswire-PRWeb/ -- The Volcker Alliance and the Penn Institute for Urban Research (Penn IUR) launched a special briefing series on the impact of COVID-19 on the fiscal outlook of state and local governments.

Key Points: 
  • NEW YORK, April 20, 2020 /PRNewswire-PRWeb/ -- The Volcker Alliance and the Penn Institute for Urban Research (Penn IUR) launched a special briefing series on the impact of COVID-19 on the fiscal outlook of state and local governments.
  • "At the Volcker Alliance, we will continue to advocate for informed fiscal practices and decision-making in this pandemic period and in the recovery that lies ahead."
  • The discussion was moderated by William Glasgall , Volcker Alliance senior vice president and director of state and local initiatives, and Susan Wachter , co-director of Penn IUR.
  • The Penn Institute for Urban Research (Penn IUR) is a university-wide body that informs urban decision-making and public policy on issues of sustainable urban growth and development based on multi-disciplinary research, instruction, and outreach.